Rare bone disease patients get early access to experimental drug
NCT ID NCT07301450
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This program offers garetosmab to adults with fibrodysplasia ossificans progressiva (FOP) who finished a previous study. The goal is to provide the drug before it is officially approved. Participants must meet specific health criteria to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.